<DOC>
	<DOCNO>NCT01880372</DOCNO>
	<brief_summary>The purpose study evaluate role alpha lipoic acid patient moderate non-proliferative diabetic retinopathy . The primary aim study test hypothesis addition alpha lipoic acid diabetic patient 's therapeutic regimen decrease progression diabetic retinopathy preserve visual acuity .</brief_summary>
	<brief_title>The Use Alpha Lipoic Acid Treatment Prevention Diabetic Retinopathy</brief_title>
	<detailed_description>Increased production free radical depletion antioxidant commonly observe diabetic patient . Based animal study , increase production free radical tend persist even blood glucose tightly control . The rationale use potent antioxidant base observation increase oxidative stress associate hyperglycemia contribute cellular injury lead apoptosis ; consequently , lead diabetic retinopathy . Evidence animal model show alpha lipoic acid ( potent antioxidant ) effective decrease progression diabetic retinopathy reduce free radical . Therefore , hypothesize therapy exert powerful antioxidant activity provide therapeutic modality need target pathogenesis diabetic retinopathy . This study 12-month pilot study demonstrate role alpha lipoic acid patient moderate non-proliferative diabetic retinopathy . Eligible patient randomize two group , treatment control group . Patients treatment group receive 600 mg alpha lipoic acid daily routine care patient control group follow routine care . Optical coherence tomography ( OCT ) electronic visual acuity test algorithm ( ETDRS ) use measure change retinal thickness visual acuity respectively . Blood change macrophage colony stimulating factor ( M-CSF ) , vascular endothelium growth factor ( VEGF ) , Interferon 2 alpha , interleukin 6 8 also evaluate compare two group . Descriptive statistic intention treat analysis use compare treatment control group .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Individual diabetes mellitus type I type II mild moderate nonproliferative diabetic retinopathy base ETDRS grade scale Patient must 18 year old Patients severe nonproliferative proliferative diabetic retinopathy Patients macular edema Eye disease may interfere visualization fundus preretinal hemorrhage , cataract , vitreous hemorrhage Patient undergone type interventional therapy diabetic retinopathy ( Such laser photocoagulation , vitrectomy ) Amblyopia Glaucoma Patient cataract surgery within period 4 month Patients retinal disease Patients chronic administration alpha lipoic acid Known intolerance/hypersensitivity alpha lipoic acid Patient history dialysis case renal insufficiency history kidney transplantation Malignancies life threaten disease determine investigator Current history drug alcohol abuse Pregnant breast feed woman Cognitively impaired patient Participation clinical trial within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Retinopathy</keyword>
	<keyword>Free radical</keyword>
	<keyword>Retinal disease</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Protective agent</keyword>
	<keyword>Thioctic acid</keyword>
</DOC>